Jaton AL - Search Results

1

SDZ PSD 958, a novel D1 receptor antagonist with potential limbic selectivity.

Markstein R, Gull P, Rüdeberg C, Urwyler S, Jaton AL, McAllister K, Dixon AK, Hoyer D. Markstein R, et al. Among authors: jaton al. J Neural Transm (Vienna). 1996;103(3):261-76. doi: 10.1007/BF01271238. J Neural Transm (Vienna). 1996. PMID: 8739838

2

SDZ GLC 756, a novel octahydrobenzo[g]quinoline derivative exerts opposing effects on dopamine D1 and D2 receptors.

Markstein R, Gull P, Rüdeberg C, Urwyler S, Jaton AL, Kalkman HO, Dixon AK, Hoyer D. Markstein R, et al. Among authors: jaton al. J Neural Transm (Vienna). 1996;103(1-2):17-30. doi: 10.1007/BF01292613. J Neural Transm (Vienna). 1996. PMID: 9026371

3

Biochemical, behavioural, and endocrine effects of CK 204-933, a novel 8 beta-ergolene.

Markstein R, Enz A, Vigouret JM, Jaton A, Closse A, Briner U, Gull P. Markstein R, et al. J Neural Transm. 1987;69(3-4):179-99. doi: 10.1007/BF01244340. J Neural Transm. 1987. PMID: 2887630

4

Structure activity relationship and therapeutic uses of dopaminergic ergots.

Markstein R, Seiler MP, Jaton A, Briner U. Markstein R, et al. Neurochem Int. 1992 Mar;20 Suppl:211S-214S. doi: 10.1016/0197-0186(92)90241-i. Neurochem Int. 1992. PMID: 1365428 Review. No abstract available.

5

Pharmacological profile of the abeorphine 201-678, a potent orally active and long lasting dopamine agonist.

Jaton AL, Giger RK, Vigouret JM, Enz A, Frick W, Closse A, Markstein R. Jaton AL, et al. Life Sci. 1986 Jan 13;38(2):155-63. doi: 10.1016/0024-3205(86)90007-x. Life Sci. 1986. PMID: 3003474

6

Dopamine D1- and D2-receptor interaction in turning behaviour induced by dopamine agonists in 6-hydroxydopamine-lesioned rats.

Karlsson G, Jaton AL, Vigouret JM. Karlsson G, et al. Among authors: jaton al. Neurosci Lett. 1988 May 16;88(1):69-74. doi: 10.1016/0304-3940(88)90317-5. Neurosci Lett. 1988. PMID: 2969468

7

Centrally acting alpha 1-adrenoceptor agonists based on hexahydronaphth[2,3-b]-1,4-oxazines and octahydrobenzo[g]quinolines.

Nozulak J, Vigouret JM, Jaton AL, Hofmann A, Dravid AR, Weber HP, Kalkman HO, Walkinshaw MD. Nozulak J, et al. Among authors: jaton al. J Med Chem. 1992 Feb 7;35(3):480-9. doi: 10.1021/jm00081a008. J Med Chem. 1992. PMID: 1346652

8

Characterization of a novel, brain-penetrating CB1 receptor inverse agonist: metabolic profile in diet-induced obese models and aspects of central activity.

Jacobson LH, Commerford SR, Gerber SP, Chen YA, Dardik B, Chaperon F, Schwartzkopf C, Nguyen-Tran V, Hollenbeck T, McNamara P, He X, Liu H, Seidel HM, Jaton AL, Gromada J, Teixeira S. Jacobson LH, et al. Among authors: jaton al. Naunyn Schmiedebergs Arch Pharmacol. 2011 Dec;384(6):565-81. doi: 10.1007/s00210-011-0686-y. Epub 2011 Sep 25. Naunyn Schmiedebergs Arch Pharmacol. 2011. PMID: 21947251

9

Structure-activity relationships of dopaminergic 5-hydroxy-2-aminotetralin derivatives with functionalized N-alkyl substituents.

Seiler MP, Stoll AP, Closse A, Frick W, Jaton A, Vigouret JM. Seiler MP, et al. J Med Chem. 1986 Jun;29(6):912-7. doi: 10.1021/jm00156a007. J Med Chem. 1986. PMID: 3712381

10

Investigation of the influence of lithium upon the down-regulation of serotonin2 receptors in rat frontal cortex induced by long-term treatment with dibenzepin, an antidepressant without appreciable affinity to serotonin2 receptors.

Closse A, Jaton AL. Closse A, et al. Among authors: jaton al. Naunyn Schmiedebergs Arch Pharmacol. 1984 Jul;326(4):291-3. doi: 10.1007/BF00501432. Naunyn Schmiedebergs Arch Pharmacol. 1984. PMID: 6148707

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

32 results

Search Page

Filters